By: Jeffrey Kuo and Afia Naaz
Edited by: Margaux Savee
Patent invalidation is a high stakes game for the pharmaceutical industry. Patented drug sales account for about 70% ($244 billion) of pharmaceutical sales in the US, and invalidation of patents at the Patent Trial and Appeal Board (“PTAB”) has an impact on pharmaceutical share prices.
Read on for more information including:
- Comparing IPR with District Court Litigation of Pharmaceutical Patents
- Statistical Outcomes of Pharmaceutical IPRs